Skip to content

KTTA

Pasithea Therapeutics Corp.

NASDAQ · Healthcare · Biotechnology · US

$0.58
−0.07%
Ask drillr
  • Jun 2, 2026, 11:02 UTC

    The FDA granted Orphan Drug Designation to Pasithea Therapeutics' PAS-004 for the treatment of ALS.